Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company faced significant pressure following earnings, triggered by the ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

The US Food and Drug Administration has chosen Dr Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

With a demand that vaccine boosters be tested against placebos, RFK Jr. puts an old antivaccine claim at the forefront of government health policy.

Momentum is building to scale back the current recommendation that all children over 6 months old get immunized against the ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...